menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Does ApoB Trump Non-HDL Measurements?

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    Consensus is building around apolipoprotein B (apoB) as the preferred tool for gauging the effectiveness of LDL-lowering therapies. Is it accurate, reproducible and cost-effective? Host Dr. Larry Kaskel welcomes Dr. Allan Sniderman, professor of cardiology at the McGill University Health Centre in Montreal, for a noteworthy discussion about apoB and its impact on our approach to atherogenic risk management. Will this test soon become standard in a lipid panel?

    Brought to you by:

    NLA logo

     

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Consensus is building around apolipoprotein B (apoB) as the preferred tool for gauging the effectiveness of LDL-lowering therapies. Is it accurate, reproducible and cost-effective? Host Dr. Larry Kaskel welcomes Dr. Allan Sniderman, professor of cardiology at the McGill University Health Centre in Montreal, for a noteworthy discussion about apoB and its impact on our approach to atherogenic risk management. Will this test soon become standard in a lipid panel?

    Brought to you by:

    NLA logo

     

Facebook Comments

Schedule23 Oct 2021
Webpack App